Marcus's mailing address filed with the SEC is C/O JAFFE LABORATORIES,, 70 DOPPLER, IRVINE, CA, 92618.
Over the last 6 years, insiders at Hancock Jaffe Laboratories Inc have traded over $1,313,267 worth of Hancock Jaffe Laboratories Inc stock and bought 39,132 units worth $123,953 . The most active insiders traders include Holding, S.A. Biodyne, Robert Andrew Berman a Francis Duhay. On average, Hancock Jaffe Laboratories Inc executives and independent directors trade stock every 100 days with the average trade being worth of $3,344,125. The most recent stock trade was executed by Matthew Jenusaitis on 25 August 2021, trading 1,300 units of HJLI stock currently worth $10,010.
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.
Hancock Jaffe Laboratories Inc executives and other stock owners filed with the SEC include: